The Oncology Institute, Inc.

The Oncology Institute, Inc.

TOINYSE / NASDAQHealthcareSmall cap

$6.20+$0.04 (+0.6%)

Last close · Data as of Aug 11, 2026

Market cap
$473.9M
P/E
-7.8x
EV / EBITDA
-12.8x
Revenue
$502.7M
Net margin
-12.1%
ROCE
-38.5%

Hidden because the last close is more than three trading days older than the latest prices of its class.

The Oncology Institute, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 11 Aug 2026 close.

1M
Stale
3M
Stale
6M
Stale
1Y
Stale
5Y
Stale
  • Hidden because the last close is more than three trading days older than the latest prices of its class.

52-week range

Day change +$0.04 (+0.6%) from $6.16 to $6.20 · Last close Aug 11, 2026

Best weekday to invest, historically

The same weekly amount in TOI, bought on each weekday since 2021.

News & filings

What The Oncology Institute filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernShareholders' equity is negative: liabilities exceed assets.

Strengths

No strength stands out for this company on the data on file.

  • Prices are as of 11 Aug 2026; price-based points are paused until newer prices arrive.
  • The stored ratios (as of 11 Jun 2026) describe a profitable period while fiscal 2025 shows a net loss: the two cover different periods, so the ratio points are not shown.
  • Shareholders' equity is negative, so return on equity and debt to equity are not shown.

Prices to the 11 Aug 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other.

Read moreShow less

The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.

Sector
Healthcare
Shares outstanding
98.9M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$473.9M
P/E
-7.8x
P/B
-30.1x
EV / EBITDA
-12.8x
EV / Sales
1.1x
P/S
0.9x
52-week high
$6.41
52-week low
$2.38

Profitability

Operating margin
-7.2%
Net margin
-12.1%
EBITDA margin
-8.5%
ROE
385.5%
ROCE
-38.5%
ROIC
-71.8%
ROA
-36.8%
Asset turnover
3.05

Growth

Revenue
$502.7M
Revenue growth, 1Y
27.8%
Revenue CAGR, 3Y
25.8%
Net profit growth, 1Y
-6.3%
Free cash flow
-$27.8M

Solvency

Current ratio
1.59
Debt / Equity
-6.60
Debt / Assets
0.63
CFO / Net profit
0.41
Cash / Market cap
7.1%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$502.7M
Cost of revenue$426.3M
Gross profit$76.4M
Operating expenses$112.5M
Selling, general and administrative$105.6M
Operating income-$36.1M
Interest and other-$24.7M
Pretax income-$60.7M
Tax and other-$130.0k
Net income-$60.6M

Revenue and net profit

Revenue grew 27.8% in FY2025; net profit is the dashed line.

The Oncology Institute, Inc. revenue and net profit by fiscal year
The Oncology Institute, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$252.5M$152.0k
FY2023$324.2M-$83.1M
FY2024$393.4M-$64.7M
FY2025$502.7M-$60.6M

Cash flows

FY2025: -$24.6M from operations, -$27.8M free after investment (dashed).

The Oncology Institute, Inc. operating and free cash flow by fiscal year
The Oncology Institute, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$61.8M-$67.3M
FY2023-$36.3M-$40.9M
FY2024-$26.5M-$30.3M
FY2025-$24.6M-$27.8M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$502.7M+27.8%1Y
EBITDA
-$42.5M
Net profit
-$60.6M
Cash from operations
-$24.6M
Free cash flow
-$27.8M
Revenue CAGR, 3Y
25.8%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$502.7M-$42.5M-$60.6M-$27.8M385.5%+27.8%-6.3%

Monthly returns

Month-by-month returns of TOI across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$164.7M
Liabilities$180.4M
Equity-$15.7M
Paid-in capital$256.7M
Retained earnings-$271.4M
Treasury stock$1.0M

Market cap against peers

8 peers: same sector, nearest by size.

  1. The Oncology Institute, Inc. (this company)$473.9M
  2. CTEV$470.0M

Peers map

Healthcare companies placed by value, growth and quality; TOI highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

No company in this group has a positive P/E.

EV / Sales, for the companies without earnings

  1. CTEV5.3x
  2. The Oncology Institute, Inc. (this company)1.1x

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
The Oncology Institute, Inc.TOIthis company$473.9M-7.8x-30.1x385.5%-12.8x
AngioDynamics, Inc.ANGO$497.1M-14.6x2.7x-18.6%256.3x
Standard BioTools Inc.LAB$495.8M-6.6x1.2x-17.7%-4.7x
Evolent Health, Inc.EVH$492.7M-0.9x1.2x-128.7%-3.7x
Prothena Corporation plcPRTA$484.3M-2.0x1.7x-87.0%-1.0x
CTEVCTEV$470.0M——163.5%10.8x
OrthoPediatrics Corp.KIDS$464.9M-11.7x1.3x-11.4%-69.2x
Weave Communications, Inc.WEAV$459.1M-16.4x5.6x-34.1%-42.3x
Editas Medicine, Inc.EDIT$458.9M-2.9x16.8x-586.6%-2.2x
Peer median—-6.6x1.7x-26.3%-3.0x

Year-to-date ROI

TOI since 1 January, against earlier years.

Historical volatility

TOI's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

The Oncology Institute, Inc. operating margin by fiscal year
The Oncology Institute, Inc. operating margin by fiscal year
DateOperating margin
FY2022-28.5%
FY2023-18.6%
FY2024-15.3%
FY2025-7.2%
LineFY2025
Cost of revenueCost Of Revenue$426.3M
Gross profitGross Profit$76.4M
Operating expensesOperating Expense$112.5M
Selling, general and administrativeSelling General And Administration$105.6M
Depreciation and amortisationDepreciation And Amortization In Income Statement$6.9M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$6.9M
Total expensesTotal Expenses$538.8M
Pretax incomePretax Income-$60.7M

Learn while you research

Academy chapters picked for The Oncology Institute, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing28% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →